BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 22167207)

  • 1. Anticancer agent ellipticine combined with histone deacetylase inhibitors, valproic acid and trichostatin A, is an effective DNA damage strategy in human neuroblastoma.
    Poljakova J; Hrebackova J; Dvorakova M; Moserova M; Eckschlager T; Hrabeta J; Göttlicherova M; Kopejtkova B; Frei E; Kizek R; Stiborova M
    Neuro Endocrinol Lett; 2011; 32 Suppl 1():101-16. PubMed ID: 22167207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The mechanism of cytotoxicity and DNA adduct formation by the anticancer drug ellipticine in human neuroblastoma cells.
    Poljaková J; Eckschlager T; Hrabeta J; Hrebacková J; Smutný S; Frei E; Martínek V; Kizek R; Stiborová M
    Biochem Pharmacol; 2009 May; 77(9):1466-79. PubMed ID: 19426684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of histone deacetylase inhibitor valproic acid on the anticancer effect of etoposide on neuroblastoma cells.
    Groh T; Hrabeta J; Poljakova J; Eckschlager T; Stiborova M
    Neuro Endocrinol Lett; 2012; 33 Suppl 3():16-24. PubMed ID: 23353839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of covalent ellipticine- and doxorubicin-derived adducts in DNA of neuroblastoma cells by the ³²P-postlabeling technique.
    Stiborova M; Poljakova J; Eckschlager T; Kizek R; Frei E
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2012 Jun; 156(2):115-21. PubMed ID: 22837132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytotoxicity of and DNA adduct formation by ellipticine in human U87MG glioblastoma cancer cells.
    Martinkova E; Dontenwill M; Frei E; Stiborova M
    Neuro Endocrinol Lett; 2009; 30 Suppl 1():60-6. PubMed ID: 20027146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Histone Deacetylase Inhibitor Valproic Acid Exerts a Synergistic Cytotoxicity with the DNA-Damaging Drug Ellipticine in Neuroblastoma Cells.
    Cerna T; Hrabeta J; Eckschlager T; Frei E; Schmeiser HH; Arlt VM; Stiborová M
    Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29304031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The anticancer drug ellipticine forms covalent DNA adducts, mediated by human cytochromes P450, through metabolism to 13-hydroxyellipticine and ellipticine N2-oxide.
    Stiborová M; Sejbal J; Borek-Dohalská L; Aimová D; Poljaková J; Forsterová K; Rupertová M; Wiesner J; Hudecek J; Wiessler M; Frei E
    Cancer Res; 2004 Nov; 64(22):8374-80. PubMed ID: 15548707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of histone deacetylase inhibitors trichostatin A and valproic acid on etoposide-induced apoptosis in leukemia cells.
    Jasek E; Lis GJ; Jasinska M; Jurkowska H; Litwin JA
    Anticancer Res; 2012 Jul; 32(7):2791-9. PubMed ID: 22753739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ellipticine-loaded apoferritin nanocarrier retains DNA adduct-based cytochrome P450-facilitated toxicity in neuroblastoma cells.
    Indra R; Černá T; Heger Z; Hraběta J; Wilhelm M; Dostálová S; Lengálová A; Martínková M; Adam V; Eckschlager T; Schmeiser HH; Arlt VM; Stiborová M
    Toxicology; 2019 May; 419():40-54. PubMed ID: 30914192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histone deacetylase inhibitors induced differentiation and accelerated mineralization of pulp-derived cells.
    Duncan HF; Smith AJ; Fleming GJ; Cooper PR
    J Endod; 2012 Mar; 38(3):339-45. PubMed ID: 22341071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of hepatic cytochromes P450 in bioactivation of the anticancer drug ellipticine: studies with the hepatic NADPH:cytochrome P450 reductase null mouse.
    Stiborová M; Arlt VM; Henderson CJ; Wolf CR; Kotrbová V; Moserová M; Hudecek J; Phillips DH; Frei E
    Toxicol Appl Pharmacol; 2008 Feb; 226(3):318-27. PubMed ID: 17976674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of ellipticine-mediated resistance in UKF-NB-4 neuroblastoma cells.
    Procházka P; Libra A; Zemanová Z; Hřebačková J; Poljaková J; Hraběta J; Bunček M; Stiborová M; Eckschlager T
    Cancer Sci; 2012 Feb; 103(2):334-41. PubMed ID: 22040216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The synergistic effects of DNA-damaging drugs cisplatin and etoposide with a histone deacetylase inhibitor valproate in high-risk neuroblastoma cells.
    Groh T; Hrabeta J; Khalil MA; Doktorova H; Eckschlager T; Stiborova M
    Int J Oncol; 2015 Jul; 47(1):343-52. PubMed ID: 25963435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The anticancer drug ellipticine is a potent inducer of rat cytochromes P450 1A1 and 1A2, thereby modulating its own metabolism.
    Aimová D; Svobodová L; Kotrbová V; Mrázová B; Hodek P; Hudecek J; Václavíková R; Frei E; Stiborová M
    Drug Metab Dispos; 2007 Oct; 35(10):1926-34. PubMed ID: 17656468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxidation pattern of the anticancer drug ellipticine by hepatic microsomes - similarity between human and rat systems.
    Stiborová M; Borek-Dohalská L; Aimová D; Kotrbová V; Kukacková K; Janouchová K; Rupertová M; Ryslavá H; Hudecek J; Frei E
    Gen Physiol Biophys; 2006 Sep; 25(3):245-61. PubMed ID: 17197724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytochromes P450 reconstituted with NADPH: P450 reductase mimic the activating and detoxicating metabolism of the anticancer drug ellipticine in microsomes.
    Kotrbová V; Aimová D; Brezinová A; Janouchová K; Poljaková J; Frei E; Stiborová M
    Neuro Endocrinol Lett; 2006 Dec; 27 Suppl 2():18-22. PubMed ID: 17159771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA adduct formation by the anticancer drug ellipticine in rats determined by 32P postlabeling.
    Stiborová M; Breuer A; Aimová D; Stiborová-Rupertová M; Wiessler M; Frei E
    Int J Cancer; 2003 Dec; 107(6):885-90. PubMed ID: 14601046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rat microsomes activating the anticancer drug ellipticine to species covalently binding to deoxyguanosine in DNA are a suitable model mimicking ellipticine bioactivation in humans.
    Stiborová M; Stiborová-Rupertová M; Borek-Dohalská L; Wiessler M; Frei E
    Chem Res Toxicol; 2003 Jan; 16(1):38-47. PubMed ID: 12693029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ellipticine oxidation and DNA adduct formation in human hepatocytes is catalyzed by human cytochromes P450 and enhanced by cytochrome b5.
    Stiborová M; Poljaková J; Martínková E; Ulrichová J; Simánek V; Dvořák Z; Frei E
    Toxicology; 2012 Dec; 302(2-3):233-41. PubMed ID: 22917556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone deacetylase inhibitors valproate and trichostatin A are toxic to neuroblastoma cells and modulate cytochrome P450 1A1, 1B1 and 3A4 expression in these cells.
    Hřebačková J; Poljaková J; Eckschlager T; Hraběta J; Procházka P; Smutný S; Stiborová M
    Interdiscip Toxicol; 2009 Sep; 2(3):205-10. PubMed ID: 21217856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.